Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2101 | 2016 |
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ... Annals of Oncology 27 (4), 559-574, 2016 | 1016 | 2016 |
Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 900 | 2021 |
Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure P Armand, MA Shipp, V Ribrag, JM Michot, PL Zinzani, J Kuruvilla, ... Journal of Clinical Oncology 34 (31), 3733-3739, 2016 | 709 | 2016 |
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study A Italiano, JC Soria, M Toulmonde, JM Michot, C Lucchesi, A Varga, ... The Lancet Oncology 19 (5), 649-659, 2018 | 573 | 2018 |
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors E De Martin, JM Michot, B Papouin, S Champiat, C Mateus, O Lambotte, ... Journal of hepatology 68 (6), 1181-1190, 2018 | 437 | 2018 |
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report JM Michot, L Albiges, N Chaput, V Saada, F Pommeret, F Griscelli, ... Annals of Oncology 31 (7), 961-964, 2020 | 400 | 2020 |
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients M Delaunay, J Cadranel, A Lusque, N Meyer, V Gounant, D Moro-Sibilot, ... European Respiratory Journal 50 (2), 2017 | 391 | 2017 |
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ... JAMA oncology 5 (9), 1310-1317, 2019 | 319 | 2019 |
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma PL Zinzani, V Ribrag, CH Moskowitz, JM Michot, J Kuruvilla, ... Blood, The Journal of the American Society of Hematology 130 (3), 267-270, 2017 | 306 | 2017 |
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 282 | 2021 |
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease FX Danlos, AL Voisin, V Dyevre, JM Michot, E Routier, L Taillade, ... European Journal of Cancer 91, 21-29, 2018 | 275 | 2018 |
Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation B Hervier, J Haroche, L Arnaud, F Charlotte, J Donadieu, A Néel, ... Blood, The Journal of the American Society of Hematology 124 (7), 1119-1126, 2014 | 244 | 2014 |
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study N Delanoy, JM Michot, T Comont, N Kramkimel, J Lazarovici, R Dupont, ... The Lancet Haematology 6 (1), e48-e57, 2019 | 226 | 2019 |
PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a … CH Moskowitz, V Ribrag, JM Michot, G Martinelli, PL Zinzani, M Gutierrez, ... Blood 124 (21), 290, 2014 | 208 | 2014 |
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre … S Le Burel, S Champiat, C Mateus, A Marabelle, JM Michot, C Robert, ... European Journal of Cancer 82, 34-44, 2017 | 182 | 2017 |
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) F Bigot, E Castanon, C Baldini, A Hollebecque, A Carmona, ... European Journal of Cancer 84, 212-218, 2017 | 170 | 2017 |
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies M Collins, JM Michot, FX Danlos, C Mussini, E Soularue, C Mateus, ... Annals of Oncology 28 (11), 2860-2865, 2017 | 146 | 2017 |
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment H Picchi, C Mateus, C Chouaid, B Besse, A Marabelle, JM Michot, ... Clinical Microbiology and Infection 24 (3), 216-218, 2018 | 145 | 2018 |
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers FX Danlos, C Grajeda-Iglesias, S Durand, A Sauvat, M Roumier, D Cantin, ... Cell Death & Disease 12 (3), 258, 2021 | 135 | 2021 |